Jing-Tao Zhang Selected Research

norcantharidin

7/2015	A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
2/2015	Norcantharidin enhances TIMP‑2 anti‑vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP‑2 and MT1‑MMP.
3/2014	Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.
1/2014	Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.
5/2012	Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jing-Tao Zhang Research Topics

Disease

10	Neoplasms (Cancer) 01/2021 - 12/2002
4	Gallbladder Neoplasms (Gallbladder Cancer) 07/2017 - 05/2012
3	Neoplasm Metastasis (Metastasis) 01/2020 - 12/2002
2	Inflammation (Inflammations) 01/2017 - 01/2015
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2017 - 01/2015
2	Hemorrhage 07/2015 - 01/2015
2	Stroke (Strokes) 01/2015 - 01/2015
2	Carcinoma (Carcinomatosis) 03/2014 - 12/2002
1	Severe Fever with Thrombocytopenia Syndrome 01/2022
1	Viral Hemorrhagic Fevers (Viral Hemorrhagic Fever) 01/2022
1	Infections 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Lymphoma (Lymphomas) 01/2021
1	Multiple Myeloma 01/2021
1	Thrombosis (Thrombus) 01/2021
1	B-Cell Leukemia (Leukemia, B Cell) 01/2021
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Adenocarcinoma 07/2015
1	Hematoma 07/2015
1	Hemothorax 07/2015
1	Cardiac Tamponade 07/2015
1	Myocardial Infarction 01/2015
1	Embolism (Embolus) 01/2015
1	Death (Near-Death Experience) 01/2015
1	Prehypertension 01/2015
1	Atrial Fibrillation 01/2015
1	Hypertension (High Blood Pressure) 01/2015
1	Major Depressive Disorder (Major Depressive Disorders) 11/2013

Drug/Important Bio-Agent (IBA)

5	norcantharidinIBA 07/2015 - 05/2012
4	Proteins (Proteins, Gene)FDA Link 07/2017 - 12/2002
2	AntigensIBA 01/2021 - 01/2021
2	Biological ProductsIBA 01/2021 - 12/2002
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2017
2	triptolideIBA 01/2017 - 01/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2015 - 05/2012
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2015 - 01/2015
2	Matrix Metalloproteinases (MMPs)IBA 03/2014 - 12/2002
2	Tissue Inhibitor of Metalloproteinase-2IBA 05/2012 - 12/2002
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	Chymases (Chymase)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Tryptases (Tryptase)IBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	ProteomeIBA 03/2019
1	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 07/2015
1	Vascular Endothelial Growth Factor CIBA 07/2015
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2015
1	Messenger RNA (mRNA)IBA 07/2015
1	mF4-31C1 monoclonal antibodyIBA 07/2015
1	Sorafenib (BAY 43-9006)FDA Link 07/2015
1	Vascular Endothelial Growth Factor DIBA 07/2015
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 07/2015
1	aliskiren FDA Link 01/2015
1	AnticoagulantsIBA 01/2015
1	PaxillinIBA 01/2014
1	EphrinsIBA 01/2014
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2014
1	Escitalopram FDA Link 11/2013
1	Peptides (Polypeptides)IBA 11/2013
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 05/2012
1	Angiogenesis InhibitorsIBA 05/2012
1	AvidinIBA 12/2002
1	Biotin (Vitamin H)FDA Link 12/2002

Therapy/Procedure

6	Therapeutics 01/2021 - 01/2015
2	Immunotherapy 01/2021 - 01/2021
2	Aftercare (After-Treatment) 02/2015 - 03/2014
1	Catheter Ablation 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Blood Transfusion (Blood Transfusions) 07/2015
1	Length of Stay 07/2015